Polymorphisms of Cx3CR1 and CXCR6 receptors in relation to HAART therapy of HIV type 1 patients

AIDS Research and Human Retroviruses

Volumn 23, Issue 8, 2007, Pages 1026-1032

  Passam, A M ^a   Sourvinos, G ^a   Krambovitis, E ^b,c   Miyakis, S ^d   Stavrianeas, N ^e   Zagoreos, I ^e   Spandidos, D A ^a  

^a UNIVERSITY OF CRETE   (Greece)

^b INSTITUTE OF MOLECULAR BIOLOGY AND BIOTECHNOLOGY   (Greece)

^c UNIVERSITY OF THESSALY   (Greece)

^d UNIVERSITY OF NEW SOUTH WALES   (Australia)

^e A Syngros Hospital   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CHEMOKINE RECEPTOR CX3CR1; CHEMOKINE RECEPTOR CXCR6; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CD4 LYMPHOCYTE COUNT; CONTROLLED STUDY; FEMALE; HAPLOTYPE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN POLYMORPHISM; TREATMENT RESPONSE; VIRUS LOAD;

ADULT; AGED; ALLELES; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; KAPLAN-MEIERS ESTIMATE; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; RECEPTORS, CHEMOKINE; RECEPTORS, VIRUS; VIRAL LOAD;

EID: 34848914461     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.2006.0248     Document Type: Article

References (39)

1. Krambovitis E, Porichis F, and Spandidos DA: HIV entry inhibitors: A new generation of antiretroviral drugs. Acta Pharmacol Sin 2005;26:1165-1173.
2. Moser B and Loetscher P: Lymphocyte traffic control by chemokines. Nat Immunol 2001;2:123-128.
3. Dean M, Carrington M, Winkler C, et al.: Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Hemophilia Growth and Development Study, Multicenter AIDS Cohort Study, Multicenter Hemophilia Cohort Study, San Francisco City Cohort, ALIVE Study. Science 1996;273:1856-1862.
4. Huang Y, Paxton WA, Wolinsky SM, et al.: The role of a mutant CCR5 allele in HIV-1 transmission and disease progression. Nat Med 1996;2:1240-1243.
5. Ioannidis JP, Rosenberg PS, Goedert JJ, et al.: Effects of CCR5-delta32, CCR2-64I, and SDF-1 3′ A alleles on HIV-1 disease progression: An international meta-analysis of individual-patient data. Ann Intern Med 2001;135:782-795.
6. Liu R, Paxton WA, Choe S, et al.: Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell 1996;86:367-377.
7. Samson M, Libert F, Doranz BJ, et al.: Resistance to HIV-1 infection in caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature 1996;382:722-725.
8. Stewart GJ, Ashton LJ, Biti RA, et al.: Increased frequency of CCR-5 delta 32 heterozygotes among long-term non-progressors with HIV-1 infection. The Australian Long-Term Non-Progressor Study Group. AIDS 1997;11:1833-1838.
9. Berger EA, Murphy PM, and Farber JM: Chemokine receptors as HIV-1 coreceptors: Roles in viral entry, tropism, and disease. Annu Rev Immunol 1999;17:657-700.
10. Zafiropoulos A, Baritaki S, Sioumpara M, Spandidos DA, and Krambovitis E: V3 induces in human normal cell populations an accelerated macrophage-mediated proliferation - apoptosis phenomenon of effector T cells when they respond to their cognate antigen. Biochem Biophys Res Commun 2001;281:63-70.
11. Krambovitis E and Spandidos DA: HIV-1 infection: Is it time to reconsider our concepts? Int J Mol Med 2006;18:3-8.
12. An P, Nelson GW, Wang L, et al.: Modulating influence on HIV/AIDS by interacting RANTES gene variants. Proc Natl Acad Sci USA 2002;99:10002-10007.
13. Motsinger A, Haas DW, Stanic AK, et al.: CD1d-restricted human natural killer T cells are highly susceptible to human immunodeficiency virus 1 infection. J Exp Med 2002;195:869-879.
14. Liao F, Alkhatib G, Peden KW, et al.: STRL33, A novel chemokine receptor-like protein, functions as a fusion cofactor for both macrophage-tropic and T cell line-tropic HIV-1. J Exp Med 1997;185:2015-2023.
15. Begaud E, Feindirongai G, Versmisse P, et al.: Broad spectrum of coreceptor usage and rapid disease progression in HIV-1-infected individuals from Central African Republic. AIDS Res Hum Retroviruses 2003;19:551-560.
16. Sharron M, Pohlmann S, Price K, et al.: Expression and coreceptor activity of STRL33/Bonzo on primary peripheral blood lymphocytes. Blood 2000;96:41-49.
17. Johnston B, Kim CH, Soler D, Emoto M, and Butcher EC: Differential chemokine responses and homing patterns of murine TCR alpha beta NKT cell subsets. J Immunol 2003;171:2960-2969.
18. Kim CH, Johnston B, and Butcher EC: Trafficking machinery of NKT cells: Shared and differential chemokine receptor expression among V alpha 24(+)V beta 11(+) NKT cell subsets with distinct cytokine-producing capacity. Blood 2002;100:11-16.
19. Kim CH, Kunkel EJ, Boisvert J, et al.: Bonzo/CXCR6 expression defines type 1-polarized T-cell subsets with extralymphoid tissue homing potential. J Clin Invest 2001;107:595-601.
20. Duggal P, An P, Beaty TH, et al.: Genetic influence of CXCR6 chemokine receptor alleles on PCP-mediated AIDS progression among African Americans. Genes Immun 2003;4:245-250.
21. Vicenzi E, Alfano M, Ghezzi S, et al.: Divergent regulation of HIV-1 replication in PBMC of infected individuals by CC chemokines: Suppression by RANTES, MIP-1alpha, and MCP-3, and enhancement by MCP-1. J Leukoc Biol 2000;68:405-412.
22. Cinque P, Vago L, Mengozzi M, et al.: Elevated cerebrospinal fluid levels of monocyte chemotactic protein-1 correlate with HIV-1 encephalitis and local viral replication. AIDS 1998;12:1327-1332.
23. Conant K, Garzino-Demo A, Nath A, et al.: Induction of monocyte chemoattractant protein-1 in HIV-1 Tat-stimulated astrocytes and elevation in AIDS dementia. Proc Natl Acad Sci USA 1998; 95:3117-3121.
24. Monteiro de Almeida S, Letendre S, Zimmerman J, et al.: Dynamics of monocyte chemoattractant protein type one (MCP-1) and HIV viral load in human cerebrospinal fluid and plasma. J Neuroimmunol 2005;169:144-152.
25. Blanpain C, Migeotte I, Lee B, et al.: CCR5 binds multiple CC-chemokines: MCP-3 acts as a natural antagonist. Blood 1999;94: 1899-1905.
26. Schols D, Proost P, Van Damme J, and De Clercq E: RANTES and MCP-3 inhibit the replication of T-cell-tropic human immunodeficiency virus type 1 strains (SF-2, MN, and HE). J Virol 1997;71:7300-7304.
27. Modi WS, Goedert JJ, Strathdee S, et al.: MCP-1-MCP-3-Eotaxin gene cluster influences HIV-1 transmission. AIDS 2003;17:2357-2365.
28. Combadiere B, Faure S, Autran B, Debre P, and Combadiere C: The chemokine receptor CX3CR1 controls homing and anti-viral potencies of CD8 effector-memory T lymphocytes in HIV-infected patients. AIDS 2003;17:1279-1290.
29. Cotter R, Williams C, Ryan L, et al.: Fractalkine (CX3CL1) and brain inflammation: Implications for HIV-1-associated dementia. J Neurovirol 2002;8:585-598.
30. Garin A, Tarantino N, Faure S, et al.: Two novel fully functional isoforms of CX3CR1 are potent HIV coreceptors. J Immunol 2003;171:5305-5312.
31. Faure S, Meyer L, Costagliola D, et al.: Rapid progression to AIDS in HIV + individuals with a structural variant of the chemokine receptor CX3CR1. Science 2000;287:2274-2277.
32. Singh KK, Hughes MD, Chen J, and Spector SA: Genetic polymorphisms in CX3CR1 predict HIV-1 disease progression in children independently of CD4+ lymphocyte count and HIV-1 RNA load. J Infect Dis 2005;191:1971-1980.
33. Brumme ZL, Dong WW, Chan KJ, et al.: Influence of polymorphisms within the CX3CR1 and MDR-1 genes on initial antiretroviral therapy response. AIDS 2003;17:201-208.
34. Vidal F, Vilades C, Domingo P, et al.: Spanish HIV-1-infected long-term nonprogressors of more than 15 years have an increased frequency of the CX3CR1 2491 variant allele. J Acquir Immune Defic Syndr 2005;40:527-531.
35. Passam AM, Zafiropoulos A, Miyakis S, et al.: CCR2-64I and CXCL12 3′ A alleles confer a favorable prognosis to AIDS patients undergoing HAART therapy. J Clin Virol 2005;34:302-309.
36. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. February 5, 2001. HIV Clin Trials 2001;2: 227-306.
37. Apostolakis S, Baritaki S, Kochiadakis GE, et al.: Effects of polymorphisms in chemokine ligands and receptors on susceptibility to coronary artery disease. Thromb Res 2007;119:63-71.
38. McDermott DH, Colla JS, Klecberger CA, et al.: Genetic polymorphism in CX3CR1 and risk of HIV disease. Science 2000;290: 2031.
39. Kwa D, Boeser-Nunnink B, and Schuitemaker H: Lack of evidence for an association between a polymorphism in CX3CR1 and the clinical course of HIV infection or virus phenotype evolution. AIDS 2003;17:759-761.